Douglas Cerretti - Cellcyte Genetics President
President
Dr. Douglas P. Cerretti, Ph.D., is President of CellCyte Genetics Corporationrationration. He is a biopharmaceutical research scientist with experience in drug development in inflammation and cancer. From 1984 to 2002, he served with Immunex, and, after Immunex acquisition in 2002, with Amgen in positions ranging from Staff Scientist through Scientific Director. Dr. Cerretti retired from Amgen in 2007. He is the author or coauthor of more than 100 scientific publications and has over 40 issued US Patents to his name since 2010.
| Age | 61 |
| Tenure | 14 years |
| Professional Marks | Ph.D |
| Phone | 425-519-3755 |
| Web | http://www.cellcyte.com |
Cellcyte Genetics Management Efficiency
The company has return on total asset (ROA) of (415.29) % which means that it has lost $415.29 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (22.9) %, meaning that it created substantial loss on money invested by shareholders. Cellcyte Genetics' management efficiency ratios could be used to measure how well Cellcyte Genetics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 11 records | PRESIDENT Age | ||
| William Conkling | Summit Hotel Properties | 48 | |
| Amy Rock | Cumberland Pharmaceuticals | N/A | |
| Christopher Eng | Summit Hotel Properties | 53 | |
| Jonathan Stanner | Summit Hotel Properties | 43 | |
| Carl Mayfield | Park Hotels Resorts | 60 | |
| Leo Pavliv | Cumberland Pharmaceuticals | 54 | |
| Greg Dowell | Summit Hotel Properties | 50 | |
| Paul Ruiz | Summit Hotel Properties | 58 | |
| Gregory Dowell | Summit Hotel Properties | 52 | |
| Sean DellOrto | Park Hotels Resorts | 49 | |
| Craig Aniszewski | Summit Hotel Properties | 57 | |
Management Performance
| Return On Equity | -22.9 | |||
| Return On Asset | -415.29 |
Cellcyte Genetics Management Team
Elected by the shareholders, the Cellcyte Genetics' board of directors comprises two types of representatives: Cellcyte Genetics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cellcyte. The board's role is to monitor Cellcyte Genetics' management team and ensure that shareholders' interests are well served. Cellcyte Genetics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cellcyte Genetics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Fluke, Chairman, Interm CEO and Chairman of Audit Committee | ||
| Randy Lieber, Principal Accounting Officer, Director | ||
| Douglas Cerretti, President, Chief Science Officer and Director of Bus. Devel. |
Cellcyte Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Cellcyte Genetics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -22.9 | |||
| Return On Asset | -415.29 | |||
| Current Valuation | 545.78 K | |||
| Shares Outstanding | 82.33 M | |||
| Price To Earning | (0.90) X | |||
| EBITDA | (75.44 K) | |||
| Net Income | (141.63 K) | |||
| Total Debt | 537.55 K | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (49.67 K) |
Pair Trading with Cellcyte Genetics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cellcyte Genetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cellcyte Genetics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to CarMax could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CarMax when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CarMax - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CarMax Inc to buy it.
The correlation of CarMax is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CarMax moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CarMax Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CarMax can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in Cellcyte OTC Stock
If you are still planning to invest in Cellcyte Genetics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cellcyte Genetics' history and understand the potential risks before investing.
| CEOs Directory Screen CEOs from public companies around the world | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |